The Journal of Japan Atherosclerosis Society
Online ISSN : 2185-8284
Print ISSN : 0386-2682
ISSN-L : 0386-2682
Effects of Heparin and Gabexate Mesilate on Apolipoprotein B-48 Metabolism in Hemodialysis Patients
Toshihlko MIYAISusumu YUKAWAAkefumi MAEDAKazunori YUKAWATakao MAEDAHiroshi NOMOTO
Author information
JOURNAL FREE ACCESS

1985 Volume 13 Issue 4 Pages 889-894

Details
Abstract

We reported that apolipoprotein (apo) B-48 mainly derived from small intestine in human was frequently accumulated in the triglyceride (TG) rich lipoproteins (Lps), such as very low density Lps (VLDL) and intermediate density Lps (IDL), in uremics and the accumulation of apo B-48 was increased at peroral olive-oil load and decreased or disappeared after hemodialysis using heparin as an anticoagulant.
The present study was undertaken to investigate the metabolic difference of apo B-48 between heparin-dialysis and gabexate mesilate (FOY)-dialysis without lipolytic function in hemodialysis patients with apo B-48.
After 12 hr starvation, fasting sera were obtained at 0 and 2hr during regular hemodialysis. VLDL, IDL and low density Lps were isolated by sequential ultracentrifugation and used for chemical analysis on 3.5% polyacrylamide-gel electrophoresis in 0.1% SDS to detect apo B subclasses.
Heparin-dialysis caused a decrease in serum TG, VLDL and IDL levels but not FOY-dialysis. Free fatty acids (FFA) was significantly increased at 2hr later by heparin-dialysis whereas FOY-dialysis at 2hr had only a slight increase in FFA. In patients with normo- or hypo-triglyceridemia, apo B-48 in TG-rich Lps was disappeared by heparin-dialysis but apo B-48 remained unchanged in patients with hypertriglyceridemia. On the other hand, FOY-dialysis did not affect the apo B-48 accumulation regardless of serum TG levels.
These results demonstrated that heparin-dialysis is effective for improving apo B-48 accumulation in TG-rich Lps by lipolytic function together with the removal of uremic toxins in hemodialysis patients.

Content from these authors
© Japan Atherosclerosis Society
Previous article Next article
feedback
Top